{"filing":{"accession_number":"0001193125-26-388631","cik":"0001783328","ticker":"TCRX","company_name":"TScan Therapeutics, Inc.","form":"8-K","filing_date":"2026-09-11","report_date":"2026-09-08","primary_document":"d171735d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1783328/000119312526388631/d171735d8k.htm"},"events":[{"id":32823,"run_id":30175,"accession_number":"0001193125-26-388631","anchor_item_number":"5.02","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The disclosure centers on a Compensation Committee-approved retention program providing cash awards ($822,000 to Dr. MacBeath and $416,000 to Dr. Zdraveski) and equity-based awards (2,400,000 and 1,050,000 RSUs respectively) to named executives. This is a compensatory arrangement for directors and officers under Item 5.02(e), distinct from a departure or appointment. The material value and milestone-based vesting structure make this a significant executive compensation event.","company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","filing_date":"2026-09-11","form":"8-K","submitted_at":null,"items":[{"id":36091,"accession_number":"0001193125-26-388631","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The disclosure centers on a Compensation Committee-approved retention program providing cash awards ($822,000 to Dr. MacBeath and $416,000 to Dr. Zdraveski) and equity-based awards (2,400,000 and 1,050,000 RSUs respectively) to named executives. This is a compensatory arrangement for directors and officers under Item 5.02(e), distinct from a departure or appointment. The material value and milestone-based vesting structure make this a significant executive compensation event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-11T12:02:15.086805+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36091,"accession_number":"0001193125-26-388631","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The disclosure centers on a Compensation Committee-approved retention program providing cash awards ($822,000 to Dr. MacBeath and $416,000 to Dr. Zdraveski) and equity-based awards (2,400,000 and 1,050,000 RSUs respectively) to named executives. This is a compensatory arrangement for directors and officers under Item 5.02(e), distinct from a departure or appointment. The material value and milestone-based vesting structure make this a significant executive compensation event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-11T12:02:15.086805+00:00","company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","filing_date":"2026-09-11"}]}